MDNAF - Medicenna Therapeutics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3100
+0.0300 (+2.34%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.2800
Open1.3200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.2959 - 1.5200
52 Week Range0.5060 - 1.7400
Volume149,250
Avg. Volume16,107
Market Cap44.787M
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.1650
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma

    TORONTO and HOUSTON, Nov. 18, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will host a lunchtime seminar led by key opinion leaders ("KOL"'s) to highlight the current treatment options for recurrent glioblastoma ("rGBM") and the clinical benefits seen with MDNA55, an IL4 receptor targeted therapy in this setting. In addition to the Principal Investigators of the recently completed Phase 2b clinical trial, Dr. John Sampson and Dr. Santosh Kesari, the co-inventor of MDNA55 Dr. Raj Puri, will also participate in the symposium.

  • CNW Group

    Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology

    Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology

  • CNW Group

    Medicenna Reports Second Quarter Fiscal 2020 Financial Results

    TORONTO and HOUSTON , Nov. 5, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and six months ended September 30, 2019 . The Company's fiscal Q2 2020 interim financial statements and MD&A will be available on SEDAR. "This quarter has been an exceptionally productive period for Medicenna as we significantly advance MDNA55 as an innovative treatment paradigm for patients with end-stage recurrent glioblastoma (rGBM).

  • The Non-Executive Independent Director of Medicenna Therapeutics Corp. (TSE:MDNA), Albert Beraldo, Just Bought 800% More Shares
    Simply Wall St.

    The Non-Executive Independent Director of Medicenna Therapeutics Corp. (TSE:MDNA), Albert Beraldo, Just Bought 800% More Shares

    Investors who take an interest in Medicenna Therapeutics Corp. (TSE:MDNA) should definitely note that the...

  • CNW Group

    Medicenna Announces Closing of Public Offering of $6,900,000

    TORONTO and HOUSTON , Oct. 17, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce the closing of its previously announced public offering of units (the "Units") of the Company (the "Offering") including the full exercise of the Agent's overallotment option. The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc. (the "Lead Agent"), Mackie Research Capital Corporation and Haywood Securities Inc. (together with the Lead Agent, the "Agents") and the Company.

  • CNW Group

    Medicenna Announces Filing of Final Short Form Prospectus

    TORONTO and HOUSTON , Oct. 11, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNA.TO) (MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has filed a (final) short form prospectus (the "Prospectus") which has been receipted by the regulatory authorities in each of the provinces of British Columbia , Alberta and Ontario , in connection with the marketed offering (the "Offering") of units of the Company ("Units"). A copy of the Prospectus is available under the Company's profile at www.sedar.com. Pursuant to the Offering, the Company intends to issue a minimum of 3,076,924 Units and a maximum of 4,615,386 Units at a price of CDN$1.30 per Unit for minimum gross proceeds of CDN$4,000,001 and maximum gross proceeds of CDN$6,000,002 .

  • CNW Group

    Medicenna Announces Pricing of Marketed Offering of Units

    TORONTO and HOUSTON , Oct. 2, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce today that it has priced its previously announced marketed offering (the "Offering") of units of the Company ("Units").  The Company intends to issue Units at a price of CDN$1.30 per Unit. Each Unit is comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant").

  • Medicenna Therapeutics (TSE:MDNA) Will Have To Spend Its Cash Wisely
    Simply Wall St.

    Medicenna Therapeutics (TSE:MDNA) Will Have To Spend Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • PR Newswire

    Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference

    TORONTO, Sept. 30, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, announces the presentation of new pre-clinical data from its IL-2 Superkine program. The data was presented as a poster entitled "Long-acting MDNA109: Emerging IL-2 Superkines displaying potent anti-tumoral responses" this past weekend on September 27th, 2019 at the International Cancer Immunotherapy Conference held in Paris, France. "In preclinical studies, we have combined MDNA109 variants with checkpoint inhibitors and we see very dramatic cure rates in mice," states Dr. Minh To.

  • PR Newswire

    Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform

    TORONTO, Sept. 26, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company developing first-in-class Superkines and Empowered Cytokines, today announced the publication of a peer-reviewed article in last month's edition of Nature Communications providing independent third-party validation of Medicenna's IL-2 Superkine platform, MDNA109. The publication titled "A next-generation tumor-targeting IL-2 preferentially promotes tumor infiltrating CD8+ T-cell response and effective tumor control" describes the safety, efficacy, pharmacokinetics, immunogenicity as well as efficacy profile in different tumor models of long-acting variants of MDNA109 including fusions to antibodies to create tumor targeted immunocytokines.

  • CNW Group

    Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

    TORONTO and HOUSTON , Sept 25, 2019 /CNW/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company developing first-in-class Superkines and Empowered Cytokines, today presented updated clinical results from its Phase 2b clinical trial of MDNA55, an IL4-guided toxin, in patients with recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at the Inaugural Targeting Innate Immunity Congress held from September 23-25, 2019 in Cambridge, MA. The presentation by Dr. Fahar Merchant , President & CEO of Medicenna, focused on updated efficacy results from the Phase 2b clinical trial MDNA55-05 in rGBM patients using the interleukin 4 receptor (IL4R) as an immunotherapy target, as it is overexpressed in glioblastoma as well as in cells that make up the brain tumor microenvironment (TME).

  • CNW Group

    Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

  • PR Newswire

    Medicenna to Present MDNA19 Pre-clinical Update at the 5th Annual International Cancer Immunotherapy Conference

    TORONTO and HOUSTON, Sept. 17, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present an update on the lead candidate from its IL-2 superkine platform, MDNA19, at the International Cancer Immunotherapy Conference to be held from September 25-28, 2019 in Paris, France. The conference is co-sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR).

  • PR Newswire

    Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress

    TORONTO and HOUSTON, Sept. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Targeting Innate Immunity Congress to be held on September 24 and 25, 2019 in Cambridge, MA. The presentation will discuss recent clinical data on survival outcomes and therapeutic benefit from MDNA55 in rGBM patients, a uniformly fatal type of brain cancer. Medicenna's lead candidate, MDNA55, simultaneously targets the interleukin-4 receptor (IL-4R), which is over-expressed by tumor cells and its supportive tumor microenvironment (TME) which hides the tumor from the immune system.

  • Zacks Small Cap Research

    MDNA.TO: Meeting Soon with the FDA to Discuss Regulatory Path Forward for MDNA55…

    Medicenna Therapeutics Corp. (MDNA.TO) (MDNAF) is a clinical stage immuno-oncology company developing novel versions of the cytokines Interleukin (IL)-2, IL-4, and IL-13, which they term ‘Superkines’. The Superkines can be utilized as monotherapies, used in combination with other immune modulating agents (e.g., checkpoint inhibitor antibodies), or fused with toxic agents to generate ‘Empowered Cytokines’ (EC) that precisely deliver cell-killing moieties to tumors. MDNA55: This is the company’s lead EC asset and consists of an engineered IL-4 with increased affinity to its receptor fused to a fragment of the tumor killing Pseudomonas exotoxin as a payload.

  • CNW Group

    Medicenna Reports First Quarter Fiscal 2020 Financial Results

    OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three months ended June 30, 2019 . The Company's fiscal Q1 2020 interim financial statements and MD&A will be available on SEDAR. "We are delighted with the exceptional milestones that we have accomplished during the first fiscal quarter of 2020, including very positive interim Phase 2b results for MDNA55 in recurrent Glioblastoma (rGBM) patients and selection of MDNA19 as our second immuno-oncology clinical candidate," said Dr. Fahar Merchant , President and Chief Executive Officer, Medicenna Therapeutics.

  • CNW Group

    Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform

    TORONTO and HOUSTON , July 31, 2019 /CNW/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, today announced the selection of MDNA19 (formerly, MDNA109-LA1) as its second immuno-oncology clinical candidate for the treatment of cancer. MDNA19 is a best-in-class long-acting IL-2 developed from Medicenna's Superkine platform that has shown unique ability to selectively stimulate cancer killing immune cells without the limitations seen with other long-acting IL-2 programs.